Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease…
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in…
HSINCHU, March 24, 2026 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane),…
SINGAPORE, Feb. 27, 2026 /PRNewswire/ -- Cynosure Lutronic, a global leader in energy-based medical aesthetic devices, announced today that Clarity II, its dual-wavelength long-pulse laser…
February 27, 2026 09:15 ET | Source: SEALSQ Geneva, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES)…
TOKYO and NEW YORK, Feb. 24, 2026 /PRNewswire/ -- MSIG USA and Mitsui Sumitomo Insurance Company, Limited (MSI Japan), collectively referred to…
ASHBURN, Va., Feb. 1, 2026 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced…
January 19, 2026 02:00 ET | Source: RIBER Riber receives a new order from Japan for MBE 6000 to scale…
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on…
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved…